Switching from Metoprolol Succinate to Bisoprolol

Introduction to Beta-Blocker Switching

The American Heart Association recommends switching from metoprolol succinate 50 mg to bisoprolol 5 mg without titration, as this represents an appropriate dose conversion and both are long-acting beta-blockers with similar pharmacokinetic profiles 1

Bisoprolol is approximately 5-10 times more potent than metoprolol on a milligram-per-milligram basis, making 5 mg of bisoprolol roughly equivalent to 50 mg of metoprolol succinate 1
Both medications are long-acting formulations, which allows for direct substitution without overlap or washout periods 1
The standard starting range for AFib and heart failure is 50-200 mg daily for metoprolol succinate, and bisoprolol 5 mg is within the therapeutic range of 2.5-10 mg daily for the same indications 2, 3

For stable patients on long-acting beta-blockers, immediate switching without titration is the standard approach because both drugs provide 24-hour beta-blockade coverage, minimizing the risk of rebound tachycardia or sympathetic surge 1
The American College of Cardiology recommends bisoprolol and metoprolol succinate for heart failure with reduced ejection fraction, with proven mortality benefit 2, 3

Monitor resting heart rate, targeting <80 bpm for symptomatic AFib management, within 48-72 hours after switching 4, 1
Monitor blood pressure, watching for hypotension, within 48-72 hours after switching 1
Assess for symptoms of bradycardia, such as dizziness, fatigue, or syncope, within 48-72 hours after switching 2, 1
Ensure no signs of heart failure decompensation, such as increased dyspnea, edema, or weight gain, within 48-72 hours after switching 2, 3

Bisoprolol has lower CNS penetration, resulting in reduced blood-brain barrier crossing and fewer CNS side effects, such as fatigue, depression, or sleep disturbances 1
Bisoprolol has higher beta-1 selectivity, which is beneficial if the patient develops respiratory issues 2, 1
Bisoprolol has a longer half-life, providing more consistent 24-hour rate control compared to metoprolol succinate 1
The European Society of Cardiology recommends bisoprolol for heart failure with reduced ejection fraction, with proven mortality benefit 2, 3

The American Heart Association recommends verifying the intentional use of dual antiplatelet/anticoagulation therapy, as bleeding risk is substantially elevated 2
Monitor for hypotension when combining bisoprolol with bumetanide, a loop diuretic 2

Do not use a 1:1 dose conversion, as this would cause severe bradycardia and hypotension 1
Do not overlap both beta-blockers for several days, as this creates excessive beta-blockade and increases the risk of bradycardia 1
Avoid abrupt cessation of metoprolol without starting bisoprolol, as this could precipitate rebound tachycardia or ischemia in a post-CABG patient 2

Reassess at 1-2 weeks and consider dose adjustment if heart rate remains >80 bpm at rest, symptomatic bradycardia occurs, hypotension develops, or heart failure symptoms worsen 3, 1